RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Tamoxifen in Estrogen Receptor-Positive Breast Cancer: 10 Years Superior to 5 Years
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 13
OP 14
DO 10.1177/155989771306007
UL http://mdc.sagepub.com/content/13/6/13.2.abstract
AB Ten years of adjuvant tamoxifen is superior to 5 years in reducing the rates of late recurrence and death in women with estrogen receptor (ER)-positive breast cancer. Breast cancer mortality is reduced by about one third over 15 years when women with ER-positive tumors are treated with 5 years of adjuvant tamoxifen. The effect of an additional 5 years of treatment on breast cancer recurrence and death was examined in the randomized Phase 3 Adjuvant Tamoxifen: To Offer More? study [aTTom; ISRCTN17222211; Gray RG et al. J Clin Oncol 2013 (suppl; abstr 5)]